Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer

    NEXT STORY
    OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation
    PREV STORY
    Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Bavarian Nordic A/S – Notice Convening Ordinary General Meeting

    COPENHAGEN, Denmark, 26 March, 2018 - Pursuant to Articles 10-14 of the Articles of ...

    author_avatar
    NASDAQ Market News

    Vaxil Provides Pre-Clinical and Business Update

    author_avatar
    NASDAQ Market News

    Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology

    Pharmacokinetic data supports once-daily dosingLong-term use of DCCR not associated with compromised glycemic control ...

    author_avatar
    NASDAQ Market News